Phase II study of asparagine-glycine-arginine-human tumor necrosis factor α, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma

Journal of Clinical Oncology

Volumn 28, Issue 15, 2010, Pages 2604-2611

  Gregorc, Vanesa ^a   Zucali, Paolo A ^a   Santoro, Armando ^a   Ceresoli, Giovanni L ^a   Citterio, Giovanni ^a   De Pas, Tommaso M ^a   Zilembo, Nicoletta ^a   De Vincenzo, Fabio ^a   Simonelli, Matteo ^a   Rossoni, Gilda ^a   Spreafico, Anna ^a   Viganò, Maria Grazia ^a   Fontana, Floriana ^a   De Braud, Filippo G ^a   Bajetta, Emilio ^a   Caligaris Cappio, Federico ^a   Bruzzi, Paolo ^a   Lambiase, Antonio ^a   Bordignon, Claudio ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINE GLYCINE ARGININE TUMOR NECROSIS FACTOR ALPHA; MICROSOMAL AMINOPEPTIDASE; PEMETREXED; UNCLASSIFIED DRUG; HYBRID PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA, CNGRC FUSION PROTEIN, HUMAN; TUMOR NECROSIS FACTOR-ALPHA, CNGRC FUSION PROTEIN, HUMAN;

ADULT; AGED; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; ASCITES; BLOOD VESSEL; BRONCHITIS; BRONCHOSPASM; CANDIDIASIS; CHILL; CHOLELITHIASIS; COHORT ANALYSIS; CONSTIPATION; COUGHING; CYSTITIS; DEHYDRATION; DIARRHEA; DISEASE CONTROL; DYSESTHESIA; DYSPEPSIA; DYSPHONIA; DYSPNEA; EMPYEMA; EPISTAXIS; FAINTNESS; FATIGUE; FEMALE; FEVER; GASTRITIS; HEADACHE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE EXTRASYSTOLE; HERPES SIMPLEX; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOGLYCEMIA; HYPONATREMIA; HYPOTENSION; INJECTION SITE REACTION; INSOMNIA; KIDNEY FAILURE; LUNG EMBOLISM; LUNG INFECTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MALIGNANT MESOTHELIOMA; NAUSEA; OLIGURIA; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PNEUMONIA; PR INTERVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SIDE EFFECT; SKIN PRURITUS; SOMNOLENCE; TUMOR GROWTH; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MESOTHELIOMA; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PLEURA TUMOR;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956414169     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.3649     Document Type: Article

References (47)

1. Carswell EA, Old LJ, Kassel RL, et al: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72:3666-3670, 1975
2. Lejeune FJ, Lienard D, Matter M, et al: Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6:6, 2006
3. Creaven PJ, Brenner DE, Cowens JW, et al: A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother Pharmacol 23:186-191, 1989 (Pubitemid 19076605)
4. Gamm H, Lindemann A, Mertelsmann R, et al: Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy. Eur J Cancer 27:856-863, 1991
5. Kimura K, Taguchi T, Urushizaki I, et al: Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 20:223-229, 1987 (Pubitemid 17163399)
6. Mittelman A, Puccio C, Gafney E, et al: A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion. Invest New Drugs 10:183-190, 1992
7. Schwartz JE, Scuderi P, Wiggins C, et al: A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy. Biotherapy 1:207-214, 1989 (Pubitemid 20196464)
8. Wiedenmann B, Reichardt P, Rath U, et al: Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. J Cancer Res Clin Oncol 115:189-192, 1989 (Pubitemid 19109379)
9. Fraker DL, Alexander HR, Pass HI: Biologic therapy with TNF: Systemic administration and isolation-perfusion, in De Vita V, Hellman S, Rosenberg S, (eds): Biologic Therapy of Cancer: Principles and Practice. Philadelphia, PA, JB Lippincott, 1995, pp 329-345
10. Lienard D, Eggermont AM, Schraffordt Koops H, et al: Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 4:21-26, 1994 (suppl 1) (Pubitemid 24144669)
11. Eggermont AM, Schraffordt Koops H, Lienard D, et al: Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial. J Clin Oncol 14:2653-2665, 1996 (Pubitemid 26329649)
12. Alexander HR, Brown CK, Bartlett DL, et al: Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. Clin Cancer Res 4:2357-2362, 1998 (Pubitemid 28477899)
13. Curnis F, Sacchi A, Borgna L, et al: Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18:1185-1190, 2000
14. Corti A, Ponzoni M: Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann N Y Acad Sci 1028:104-112, 2004 (Pubitemid 40361814)
15. Colombo G, Curnis F, De Mori GM, et al: Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 277:47891-47897, 2002 (Pubitemid 36159317)
16. Curnis F, Arrigoni G, Sacchi A, et al: Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 62:867-874, 2002 (Pubitemid 34126966)
17. Rangel R, Sun Y, Guzman-Rojas L, et al: Impaired angiogenesis in aminopeptidase N-null mice. Proc Natl Acad Sci U S A 104:4588-4593, 2007 (Pubitemid 47186269)
18. van Laarhoven H, Fiedler W, Desar I, et al: Phase I and DCE-MRI evaluation of NGR-TNF, a novel vascular targeting agent, in patients with solid tumors (EORTC 16041). J Clin Oncol 26:158s, 2008 (suppl; abstr 3521)
19. Gregorc V, Citterio C, Vitali G, et al: Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur J Cancer doi:10.1016/j.ejca.2009.10.005
20. Ceresoli GL, Gridelli C, Santoro A, et al: Multidisciplinary treatment of malignant pleural mesothelioma. The Oncologist 12:850-863, 2007 (Pubitemid 47328228)
21. Curran D, Sahmoud T, Therasse P, et al: Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16:145-152, 1998 (Pubitemid 28041592)
22. Herndon JE, Green MR, Chahinian AP, et al: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113:723-731, 1998
23. Vogelzang NJ, Rusthoven JJ, Symanowsky J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644, 2003 (Pubitemid 46606305)
24. Edwards JG, Swinson DE, Jones JL, et al: Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 124:1916-1923, 2003
25. Linder C, Linder S, Munck-Wikland E, et al: Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 18:2063-2068, 1998 (Pubitemid 28344873)
26. Riedl SJ, Shi Y: Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5:897-907, 2004 (Pubitemid 39486541)
27. Robinson BWS, Lake RA: Advances in malignant mesothelioma. N Engl J Med 353:1591-1603, 2005 (Pubitemid 41434638)
28. Byrne MJ, Nowak AK: Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257-260, 2004 (Pubitemid 38262625)
29. Simon R: Optimal 2-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
30. Kaplan EL, Meier P: Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457-481, 1958
31. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996 (Pubitemid 26342716)
32. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
33. Jassem J, Ramlau R, Santoro A, et al: Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26:1698-1704, 2008
34. Manegold C, Symanowski J, Gatzemeier U, et al: Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 16:923-927, 2005 (Pubitemid 40903918)
35. Fennell D, Steele J, Sheaff M, et al: Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage. Lung Cancer 49:S220, 2005 (suppl; abstr P-397)
36. Grothey A, Hedrick EE, Mass RD, et al. Response-independent survival benefit in metastatic colorectal cancer: A comparative analysis of N9741 and AVF2107. J Clin Oncol 26:183-189, 2008
37. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nature Reviews Cancer 4:423-436, 2004 (Pubitemid 38745528)
38. Zucali PA, Ceresoli GL, Garassino I, et al: Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 112:1555-1561, 2008 (Pubitemid 351441168)
39. Jackman DM, Kindler HL, Yeap BY, et al: Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 113:808-814, 2008
40. Stebbing J, Powles T, McPherson K, et al: The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 63:94-97, 2009
41. Nowak AK, Millward MJ, Francis R, et al: Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). J Clin Oncol 26:439s, 2008 (suppl; abstr 8063)
42. Oxnard GR, Armato III SG, Kindler HL, et al: Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer 52:141-148, 2006
43. Armato III SG, Ogarek JL, Starkey A, et al: Variability in mesothelioma tumor response classification. AJR Am J Roentgenol 186:1000-1006, 2006 (Pubitemid 46100199)
44. Curnis F, Sacchi A, Corti A: Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 110:475-482, 2002 (Pubitemid 34919701)
45. Sacchi A, Gasparri A, Gallo-Stampino C, et al: Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin Cancer Res 12:175-182, 2006 (Pubitemid 43166192)
46. Gregorc V, Santoro A, Bennicelli E, et al: Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer 101:219-224, 2009
47. De Braud FG, Gregorc V, De Pas TM, et al: A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent, in combination with cisplatin in patients with solid tumors. J Clin Oncol 26:639s, 2008 (suppl; abstr 14647)